Fig 1. Progression-free survival (PFS) by treatment group for (A) all patients, (B) patients with indolent non-Hodgkin lymphoma, and (C) patients with mantle-cell lymphoma. Note: Censored values are ...

Patients with an unusually indolent form of mantle-cell lymphoma typically present with splenomegaly, bone marrow involvement, and circulating lymphoma cells but without lymphadenopathy and ...

The proteasome inhibitor bortezomib is registered in the US for use in multiple myeloma, but its antitumor activity has not been tested in patients with indolent or MANTLE-CELL LYMPHOMA (MCL).

Fast-growing lymphomas are called high-grade. Slow-growing lymphomas are called low-grade or indolent. Mantle cell lymphoma is unusual because it can look and act like both high-grade and low ...

Twenty patients (35%) had follicular lymphoma ... or refractory patients with indolent B-NHL and MCL showed prolonged lymphocytopenia and low CD4-positive T-cell counts for at least 7–9 months ...

Mantle cell lymphoma can be challenging to treat because it can manifest as either an indolent disease — known as “classical” mantle cell lymphoma — or it can develop an aggressive course ...

The simple combination of bendamustine plus rituximab (Rituxin) can replace standard therapy in patients newly diagnosed with indolent non-Hodgkin's lymphoma and mantle cell lymphoma, according to ...

In mantle cell lymphoma, it's a good regimen ... Versus CHOP Plus Rituximab as First-Line Treatment for Patients With Indolent and Mantle-Cell Lymphomas: An Open-Label, Multicentre, Randomised ...

For more rare, aggressive cancers, such as mantle cell lymphoma (MCL), that are characterized by frequent ... needed to assess the effectiveness of this strategy in MCL given the indolent course of ...

Mantle cell lymphoma grows slowly but can be hard to ... Some types are aggressive (fast-spreading) and some types are indolent (slow-spreading). How aggressive is large B-cell lymphoma?

Friday’s FDA approval of Tecartus for previously treated mantle cell lymphoma takes the ... for Yescarta in indications including indolent non-Hodgkin lymphoma and move the med earlier into ...

The medians were not reached for any of the time-to event end points for either the BR or R-CHOP/R-CVP study treatment groups by study completion. PFS rates at 5 years were 65.5% in the BR treatment ...